Procedure : 2012/2155(BUD)
Document stages in plenary
Document selected : A7-0325/2012

Texts tabled :

A7-0325/2012

Debates :

Votes :

PV 23/10/2012 - 13.13
Explanations of votes
Explanations of votes

Texts adopted :

P7_TA(2012)0376

REPORT     
PDF 200kWORD 110k
15 October 2012
PE 494.815v02-00 A7-0325/2012

on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the European Globalisation Adjustment Fund, in accordance with point 28 of the Interinstitutional Agreement of 17 May 2006 between the European Parliament, the Council and the Commission on budgetary discipline and sound financial management (application EGF/2011/015 SE/AstraZeneca from Sweden)

(COM(2012)0396 – C7-0191/2012 – 2012/2155(BUD))

Committee on Budgets

Rapporteur: Dominique Riquet

MOTION FOR A EUROPEAN PARLIAMENT RESOLUTION
 ANNEX: DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
 EXPLANATORY STATEMENT
 ANNEX: LETTER OF THE COMMITTEE ON EMPLOYMENT AND SOCIAL AFFAIRS
 RESULT OF FINAL VOTE IN COMMITTEE

MOTION FOR A EUROPEAN PARLIAMENT RESOLUTION

on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the European Globalisation Adjustment Fund, in accordance with point 28 of the Interinstitutional Agreement of 17 May 2006 between the European Parliament, the Council and the Commission on budgetary discipline and sound financial management (application EGF/2011/015 SE/AstraZeneca from Sweden)

(COM(2012)0396 – C7-0191/2012 – 2012/2155(BUD))

The European Parliament,

–   having regard to the Commission proposal to Parliament and the Council (COM(2012)0396 – C7-0191/2012),

–   having regard to the Interinstitutional Agreement of 17 May 2006 between the European Parliament, the Council and the Commission on budgetary discipline and sound financial management(1) (IIA of 17 May 2006), and in particular point 28 thereof,

–   having regard to Regulation (EC) No 1927/2006 of the European Parliament and of the Council of 20 December 2006 on establishing the European Globalisation Adjustment Fund(2) (EGF Regulation),

–   having regard to the trilogue procedure provided for in point 28 of the IIA of 17 May 2006,

–   having regard to the letter of the Committee on Employment and Social Affairs,

–   having regard to the report of the Committee on Budgets (A7-0325/2012),

A. whereas the European Union has set up the appropriate legislative and budgetary instruments to provide additional support to workers who are suffering from the consequences of major structural changes in world trade patterns and to assist their reintegration into the labour market,

B.  whereas the scope of the European Globalisation Adjustment Fund (EGF) was broadened for applications submitted from 1 May 2009 to include support for workers made redundant as a direct result of the global financial and economic crisis,

C. whereas the Union’s financial assistance to workers made redundant should be dynamic and made available as quickly and efficiently as possible, in accordance with the Joint Declaration of the European Parliament, the Council and the Commission adopted during the conciliation meeting on 17 July 2008, and having due regard for the IIA of 17 May 2006 in respect of the adoption of decisions to mobilise the EGF,

D. whereas Sweden has requested assistance for 987 redundancies, 700 of which are targeted for assistance, in AstraZeneca pharmaceutical company in Sweden,

E.  whereas the application fulfils the eligibility criteria laid down by the EGF Regulation,

1.  Agrees with the Commission that the conditions set out in Article 2(a) of the EGF Regulation are met and that, therefore, Sweden is entitled to a financial contribution under that Regulation;

2. Welcomes this call for the EGF financial contribution by the Swedish Government even though this Member State is opposed to the EGF after 2013;

3.  Notes that the Swedish authorities submitted the application for EGF financial contribution on 23 December 2011, supplemented by additional information up to 16 April 2012, and that its assessment was made available by the Commission on 16 July 2012; welcomes the fact that the evaluation process and submission of additional information by Sweden were speedy and accurate;

4. Notes that the affected enterprises are located in four of the 290 Swedish municipalities with the majority of the staff made redundant in Lund in southern Sweden; the closure of the AstraZeneca site is a heavy burden for Lund and also affects the entire pharmaceutical sector in Sweden; this development causes an imbalance in the regional labour market; unemployment increased in all affected municipalities from January 2009 to November 2011: in Lund from 2 467 to 3 025, Umeå from 3 725 to 4 539, Sodertalje from 3 100 to 5 555 and Mölndal from 1 458 to 1 663;

5.  Notes that Sweden has had a strong position in medical research and the collective redundancies in AstraZeneca had not been expected; while the worsening situation in the pharmaceutical sector due to the rising dominance of generics and outsourcing of research and development activites outside of Europe had been foreseen, the impact on AstraZeneca was more severe than anticipated;

6. Notes that the R&D activities carried out in Lund site have been transferred by AstraZeneca to Mölndal site; inquires if any of the Lund workers were offered the possibility to be employed in the enlarged site of Mölndal instead of being dismissed;

7. Welcomes the fact that, in order to provide workers with speedy assistance, the Swedish authorities decided to start the implementation of the measures on 26 October 2011 well ahead of the final decision on granting the EGF support for the proposed coordinated package;

8.  Recalls the importance of improving the employability of all workers by means of tailored training and the recognition of skills and competences gained throughout the professional career; expects the training on offer in the coordinated package to be adapted to the level and needs of the dismissed workers, especially since the majority of the dismissed workers were specialized science professionals and engineering technicians;

9.Notes that the workers dismissed from Astra Zeneca are highly skilled and educated and therefore require specific approach; regrets that the Swedish authorities do not inform about the areas in which the training measures and occupational guidance have been planned and if and how these have been adapted to the local labour markets affected by the dismissal;

10.Welcomes the fact that the social partners participated in the discussions concerning the EGF application and are expected to participate in the steering group overseeing the implementation of EGF assistance.

11.Welcomes the fact that Swedish authorities plan to organise an awareness raising campaign about activities supported by the EGF;

12.Notes that the coordinated package foresees several participation incentives to encourage participation in the measures: job search allowance of EUR 7 170 (calculated for an average of 6 months of participation) mobility allowance of EUR 500; recalls that the EGF support should be primarily allocated to training and job search as well as training programs instead of contributing directly to unemployment benefits which are the responsibility of national institutions;

13.Highlights the fact that lessons should be learned from the preparation and implementation of this and other applications addressing mass dismissals, especially with respect to the activities in anticipation of redundancies and timeliness of the preparation of EGF applications;

14.Requests the institutions involved to make the necessary efforts to improve procedural and budgetary arrangements to accelerate the mobilisation of the EGF; appreciates the improved procedure put in place by the Commission, following Parliament's request for accelerating the release of grants, aimed at presenting to the budgetary authority the Commission's assessment on the eligibility of an EGF application together with the proposal to mobilise the EGF; hopes that further improvements in the procedure will be integrated in the new Regulation on the European Globalisation Adjustment Fund (2014–2020) and that greater efficiency, transparency, visibility and follow-up of the EGF will be achieved;

15.Recalls the institutions’ commitment to ensuring a smooth and rapid procedure for the adoption of the decisions on the mobilisation of the EGF, providing one-off, time-limited individual support geared to helping workers who have been made redundant as a result of globalisation and the financial and economic crisis; emphasises the role that the EGF can play in the reintegration of workers made redundant into in the labour market;

16.Stresses that, in accordance with Article 6 of the EGF Regulation, it should be ensured that the EGF supports the reintegration of individual redundant workers into long-term employment; further stresses that the EGF assistance can co-finance only active labour market measures which lead to durable, long-term employment; reiterates that assistance from the EGF must not replace actions which are the responsibility of companies by virtue of national law or collective agreements, nor measures restructuring companies or sectors; deplores the fact that the EGF might provide an incentive for companies to replace their contractual workforce with a more precarious and short-term one;

17.Notes that the information provided on the coordinated package of personalised services to be funded from the EGF includes information on the complementarity with actions funded by the Structural Funds; reiterates its call to the Commission to present a comparative evaluation of those data in its annual reports in order to ensure full respect of the existing regulations and that no duplication of Union-funded services can occur;

18.Welcomes the fact that following repeated requests from Parliament, the 2012 budget shows payment appropriations of EUR 50 000 000 on the EGF budget line 04 05 01; recalls that the EGF was created as a separate specific instrument with its own objectives and deadlines and therefore deserves a dedicated allocation, which will avoid transfers from other budget lines, as happened in the past, which could be detrimental to the achievement of the policy objectives of the EGF;

19.Regrets the decision of the Council to block the extension of the "crisis derogation", allowing to provide financial assistance to workers made redundant as a result of the current financial and economic crisis in addition to those losing their job because of changes in global trade patterns, and allowing the increase in the rate of Union co-financing to 65% of the programme costs, for applications submitted after the 31 December 2011 deadline, and calls on the Council to reintroduce this measure without delay;

20.Approves the decision annexed to this resolution;

21.Instructs its President to sign the decision with the President of the Council and to arrange for its publication in the Official Journal of the European Union;

22.Instructs its President to forward this resolution, including its annex, to the Council and the Commission.

(1)

OJ C 139, 14.6.2006, p. 1.

(2)

OJ L 406, 30.12.2006, p. 1.


ANNEX: DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of xxx

on the mobilisation of the European Globalisation Adjustment Fund, in accordance with point 28 of the Interinstitutional Agreement of 17 May 2006 between the European Parliament, the Council and the Commission on budgetary discipline and sound financial management (application EGF/2011/015 SE/AstraZeneca from Sweden)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union

Having regard to the Interinstitutional Agreement of 17 May 2006 between the European Parliament, the Council and the Commission on budgetary discipline and sound financial management(1), and in particular point 28 thereof,

Having regard to Regulation (EC) No 1927/2006 of the European Parliament and of the Council of 20 December 2006 establishing the European Globalisation Adjustment Fund(2), and in particular Article 12(3) thereof,

Having regard to the proposal from the European Commission,

Whereas:

(1)      The European Globalisation Adjustment Fund (EGF) was established to provide additional support for workers made redundant as a result of major structural changes in world trade patterns due to globalisation and to assist them with their reintegration into the labour market.

(2)      The scope of the EGF was broadened for applications submitted from 1 May 2009 to 30 December 2011 to include support for workers made redundant as a direct result of the global financial and economic crisis.

(3)      The Interinstitutional Agreement of 17 May 2006 allows the mobilisation of the EGF within the annual ceiling of EUR 500 million.

(4)      Sweden submitted an application on 23 December 2011 to mobilise the EGF, in respect of redundancies in the enterprise AstraZeneca and supplemented it by additional information up to 16 April 2012. This application complies with the requirements for determining the financial contributions as laid down in Article 10 of Regulation (EC) No 1927/2006. The Commission, therefore, proposes to mobilise an amount of EUR 4 325 854.

(5)      The EGF should, therefore, be mobilised in order to provide a financial contribution for the application submitted by Sweden,

HAVE ADOPTED THIS DECISION:

Article 1

For the general budget of the European Union for the financial year 2012, the European Globalisation Adjustment Fund (EGF) shall be mobilised to provide the sum of EUR 4 325 854 in commitment and payment appropriations.

Article 2

This Decision shall be published in the Official Journal of the European Union.

Done at Brussels,

For the European Parliament                       For the Council

The President                                             The President

(1)

              OJ C 139, 14.6.2006, p. 1.

(2)

              OJ L 406, 30.12.2006, p. 1.


EXPLANATORY STATEMENT

I. Background

The European Globalisation Adjustment Fund has been created in order to provide additional assistance to workers suffering from the consequences of major structural changes in world trade patterns.

According to the provisions of point 28 of the Interinstitutional Agreement of 17 May 2006 on budgetary discipline and sound financial management(1) and of the Article 12 of Regulation (EC) No 1927/2006(2), the Fund may not exceed a maximum amount of EUR 500 million, drawn from any the margin under the global expenditure ceiling from the previous year, and / or from the cancelled commitment appropriations from the previous two years, excluding those related to Heading 1b. The appropriate amounts are entered into the budget as a provision as soon as the sufficient margins and/or cancelled commitments have been identified.

As concerns the procedure, in order to activate the Fund the Commission, in case of a positive assessment of an application, presents to the budgetary authority a proposal for mobilisation of the Fund and, at the same time, a corresponding request for transfer. In parallel, a trialogue could be organised in order to find an agreement on the use of the Fund and the amounts required. The trialogue can take a simplified (written) form.

II. State of play: Commission's proposal

On 16 July 2012, the Commission adopted a new proposal for a decision on the mobilisation of the EGF in favour of Sweden in order to support the reintegration in the labour market of workers made redundant due to major structural changes in world trade patterns due to globalisation.

This is the sixth application to be examined under the 2012 budget and refers to the mobilisation of a total amount of EUR 4 325 854 from the EGF for Sweden. The application cites 543 redundancies in AstraZeneca during the four-month reference period from 15 June 2011 to 15 October 2011. A further 444 redundancies (987 in total) occurred before and after the reference period and are related to the same collective redundancy procedure. The redundancies were calculated in accordance with the second indent of the second paragraph of Article 2 of Regulation (EC) No 1927/2006.

The application was presented to the Commission on 23 December 2011 and supplemented by additional information up to 16 April 2012. The Commission has concluded that the application meets the conditions for deploying the EGF as set out in Article 2(a) of Regulation (EC) No 1927/2006, and was submitted within the deadline of 10 weeks referred to in Article 5 of that Regulation.

One of the criteria for Commission's assessment was the evaluation of the link between the redundancies and major structural changes in world trade patterns due to globalisation. Swedish authorities argue that the pharmaceutical sector is increasingly affected by globalisation. The pharmaceutical industry is currently undergoing significant changes in order to retain its competitiveness in a tough environment. Many companies are in a state of transition; reorganisation, consolidation, mergers and acquisitions are being considered in order to maintain growth centres. The industry is increasingly seeking synergies to hold down the increasing costs of research and development (R&D) activities.

Swedish authrities further argue that global investments and biotechnological research are on the increase and new competitors can be found in China, Brazil and India. Prospects for R&D funding vary by region, with the US expecting growth, Europe contemplating fiscal austerity that may restrict investment for several years, and most Asian countries maintaining strong financial commitments to R&D (share of total global R&D spending in 2009-2011: US (34,71 %-34,0 %), Asia (33,6 %-35,3 %), Europe (24,1 %-23,2 %)). During the recession, the Asian R&D communities increased their R&D investment and stature. Among the global research communities, the state of R&D in the EU gives rise to most concern. Trying to recover from recession and forced to cut deficits, can in turn affect government support for R&D(3). According to Growth Consulting Company Frost & Sullivan's report of 2010(4), about 70 % of questioned pharmaceutical companies are likely to outsource manufacturing to Asia. Those markets also demand that the drugs are tested on the local population, thus the presence of R&D in Asian markets is growing.

Moreover, the Swedish authorities argue that the challenge for the pharmaceutical industry is the increasing presence of generics as patents expire for major branded products. The generic industry has recently undergone a major restructuring. Mergers and acquisitions have concentrated a growing share of the global generic market in the hands of the sector's leading players. Generic drugs are generally manufactured in low-wage Asian countries and command around 10 % of the original price once the patent expires. As a result, many companies are affected and must undergo cutbacks. The big European manufacturers concentrate on conducting the expensive clinical phases, as well as the marketing and approval process. Research activities are in a decline.

Many non-European countries are designing strategies for biosciences and industry in areas of pharmaceuticals, biotechnology and medical technology. The European companies must adapt their production to this situation. AstraZeneca (which had three R&D centres in Sweden) followed the trend and adopted a new R&D strategy in 2010. This included the necessity to focus on fewer disease areas, closures of sites (including that in Lund and Umeå) and significantly greater utilisation of external resources through outsourcing. Following the global trends, AstraZeneca also increased R&D investments in China and Russia (AZ China is the largest multinational pharmaceutical company in the prescription market in China; in 2011 AZ also announced opening a Predictive Science Centre in St. Petersburg).

The Swedish authorities argue that, in the light of the fact that Sweden had a strong position in medical research, the collective redundancies in AstraZeneca had not been expected. While the worsening situation in the pharmaceutical sector due to the rising dominance of generics had been foreseen, the impact on AstraZeneca was more severe than anticipated. AstraZeneca was considered to be a stable company due to its long and successful history, dominating Swedish science industry with one quarter of those working in life sciences being AstraZeneca employees. Furthermore, the Swedish government has for a long time promoted the location of an interdisciplinary research centre in Lund – the European Spallation Source – and AstraZeneca was expected to devote additional resources to research in Lund. Taking into consideration the great medical need in the respiratory tract/inflammation area, the closure of the R&D site in this therapy category in Lund came as a surprise.

The co-ordinated package of personalised services to be funded, including its compatibility with actions funded by the Structural Funds, includes measures for the reintegration of the 700 targeted workers into employment, such as job-search assistance, occupational guidance, training and retraining, aid for self-employment, job-search allowances, mobility allowances, and measures to stimulate older workers.

According to Swedish authorities, all the aforementioned measures combine to form a co-ordinated package of personalised services and represent active labour market measures with the aim of re-integrating the workers into the labour market. These personalised services started on 26 October 2010.

As regards the criteria contained in Article 6 of Regulation (EC) No 1927/2006, the Swedish authorities in their application:

· confirmed that the financial contribution from the EGF does not replace measures which are the responsibility of companies by virtue of national law or collective agreements;

· demonstrated that the actions provide support for individual workers and are not to be used for restructuring companies or sectors;

· confirmed that the eligible actions referred to above do not receive assistance from other EU financial instruments.

Concerning management and control systems, Sweden has notified the Commission that the financial contribution will be managed by the Swedish Public Employment Service (PES) which has been appointed as the management and payment authority. The project accounts will be examined by the Internal Audit Unit which is a separate body attached to the board of PES.

In accordance with Commission's assessment, the application fulfils the eligibility criteria set up by the EGF Regulation and recommends to the Budget Authority to approve the applications.

In order to mobilise the Fund, the Commission has submitted to the Budget Authority a transfer request for a global amount of EUR 4 325 854 from the EGF reserve line 40 02 43 in commitments to the EGF budget line 04 05 01.

The Rapporteur welcomes the fact that, following requests from the Parliament, 2012 budget shows payment appropriations (EUR 50.000.000) on the EGF budget line 04 05 01.

He reminds, in fact, that the EGF was created as a separate specific instrument with its own objectives and deadlines and that as such deserves a dedicated allocation, which will avoid transfers from other budget lines - as happened in the past - which could be detrimental to the achievement of the various policy objectives.

The IIA allows the mobilisation of the Fund within the annual ceiling of EUR 500 million.

This is sixth proposal for the mobilisation of the Fund submitted to the Budget Authority in 2012. Therefore, deducing from the appropriations available the current amount requested (EUR 4 325 854) an amount of EUR 478 320 471 still remains available until the end of 2012. This will leave more than 25% of the maximum annual amount earmarked for the EGF available for allocations during the last four months of 2012, as required by Article 12(6) of the EGF Regulation.

III. Procedure

The Commission has presented a transfer request in order to enter specific commitment appropriations in the 2012 budget, as required in Point 28 of the Interinstitutional Agreement of 17 May 2006.

The trilogue on the Commission's proposal for a Decision on the mobilisation of the EGF could take a simplified form, as provided for in Article 12(5) of the legal base, unless there is no agreement between the Parliament and the Council.

According to an internal agreement, the Employment and Social Affairs Committee (EMPL) should be associated to the process, in order to provide constructive support and contribution to the assessment of the applications from the Fund. EMPL has decided to table amendments as well as the traditional letter of opinion, to the report reflecting their position and constructive input.

The Joint Declaration of the European Parliament, the Council and the Commission, adopted during the conciliation meeting on 17 July 2008, has confirmed the importance of ensuring a rapid procedure with due respect of the Interinstitutional Agreement for the adoption of decisions on the mobilisation of the Fund

(1)

OJ C 139, 14.6.2006, p. 1.

(2)

OJ L 406, 30.12.2006, p. 1.

(3)

              2011 Global R&D Funding Forecast, www.rdmag.com

(4)

              "Dynamics in the Pharma and Biotech Industry", Frost & Sullivan, 2010, www.frost.com


ANNEX: LETTER OF THE COMMITTEE ON EMPLOYMENT AND SOCIAL AFFAIRS

EK/ic

D(2012)47877

M. Alain Lamassoure

President of the Committee on budgets

ASP 13E158

Subject: Opinion on the mobilisation of the European Globalisation Adjustment Fund (EGF) for the case EGF/2011/015 SE/Astra Zeneca from Sweden (COM(2012)396 final)

Dear Chair,

The Committee on Employment and Social Affairs (EMPL) as well as its Working Group on the EGF examined the mobilisation of the EGF for the case EGF/2011/015 SE/Astra Zeneca and adopted the following opinion.

The EMPL committee and the Working Group on the EGF are in favour of the mobilisation of the Fund concerning this request. In this respect, the EMPL committee presents some remarks without, however, putting into question the transfer of the payments.

The deliberations of the EMPL committee are based on the following considerations:

A)  Whereas this application is based on Article 2 (a) of the EGF regulation and targets for support 700 workers of the total of 987 workers dismissed within and before and after the reference period between 15 June 2011 and 15 October 2011 in the enterprise AstraZeneca.

B)  Whereas the Swedish authorities argue that the redundancies were caused by major structural changes in world trade patterns due to globalisation, which affects increasing the pharmaceutical sector;

C)  Whereas in result of globalisation, the pharmaceutical industry is currently undergoing major restructuring in order to face increased competitiveness from Asian producers;

D)  Whereas the Swedish authorities argue that weak financial commitments to research and development in the EU and the increasing presence of generics as patents expire leads to further cutbacks in the European industry, less investments in R&D, delocalisation of production and research to Asia and greater use of outsourcing;

E)  Whereas the Swedish authorities claim that the closure of the R&D site in Lund came a s a surprise given stable situation of AstraZeneca on the European markets and its dominance in science industry in Sweden:

F)  Whereas 36,43 % of the workers targeted by the measures are men and 63,57 % are women; whereas 76,57 % of the workers are between 24 and 54 years old and 23,29% of workers are older than 55 years;

G)  Whereas the occupational structure of the dismissed labour force is highly qualified and diverse with physicists, chemists, physical and engineering science technicians, computing and life science professionals constituting half of the targeted workers;

Therefore, the Committee on Employment and Social Affairs calls on the Committee on Budgets, as the committee responsible, to integrate the following suggestions in its motion for a resolution concerning the Swedish application:

1.  Welcomes this call for the EGF financial contribution by the Swedish Government even though this Member State is opposed to the EGF after 2013;

2.  Agrees with the Commission that the conditions set out in Article 2 (a) of the EGF regulation (1927/2006) are met and that, therefore, Sweden is entitled to a financial contribution under this regulation;

3.  Notes that the Swedish authorities submitted the application for EGF financial contribution on 23 December 2011 and that its assessment was made available by the European Commission on 16 July 2012; regrets the lengthy evaluation period;

4.  Regrets the decision of AstraZeneca to increase R&D investments in countries like China or Russia, reflecting a strategy that is detrimental to EU high skilled jobs and contrary to the EU 2020 strategy;

5.  Calls for trade reciprocity in trade between the EU and third countries as a an essential condition for EU companies to gain access to new non European markets;

6.  Notes that the workers dismissed from Astra Zeneca are highly skilled and educated and therefore require specific approach; regrets that the Swedish authorities do not inform about the areas in which the training measures and occupational guidance are planned and if and how these are adapted to the local labour markets affected by the dismissal;

7.  Notes that the R&D activities carried out in Lund site have been transferred by AstraZeneca to Mölndal site; inquires if any of the Lund workers were offered the possibility to be employed in the enlarged site of Mölndal instead of being dismissed;

8.  Welcomes the fact that in order to provide workers with speedy assistance, the Swedish authorities decided to start the implementation of the measures on 26 October 2011 well ahead of the final decision on granting the EGF support for the proposed coordinated package;

9.  Notes that the coordinated package foresees several participation incentives to encourage participation in the measures: job search allowance of EUR 7 170 (calculated for an average of 6 months of participation) mobility allowance of EUR 500; recalls that the EGF support should be primarily allocated to training and job search as well as training programs instead of contributing directly to unemployment benefits which are the responsibility of national institutions;

10.  Welcomes the fact that Swedish authorities plan to organise awareness raising campaign about activities supported by EGF;

Yours sincerely,

Pervenche Berès


RESULT OF FINAL VOTE IN COMMITTEE

Date adopted

10.10.2012

 

 

 

Result of final vote

+:

–:

0:

25

5

4

Members present for the final vote

Marta Andreasen, Richard Ashworth, Francesca Balzani, Reimer Böge, Zuzana Brzobohatá, Göran Färm, Eider Gardiazábal Rubial, Salvador Garriga Polledo, Jens Geier, Ivars Godmanis, Ingeborg Gräßle, Lucas Hartong, Jutta Haug, Sidonia Elżbieta Jędrzejewska, Ivailo Kalfin, Sergej Kozlík, Jan Kozłowski, Alain Lamassoure, Giovanni La Via, George Lyon, Barbara Matera, Juan Andrés Naranjo Escobar, Nadezhda Neynsky, Dominique Riquet, Potito Salatto, Alda Sousa, Helga Trüpel, Derek Vaughan, Angelika Werthmann

Substitute(s) present for the final vote

Alexander Alvaro, Jürgen Klute, Georgios Papastamkos, Nils Torvalds, Catherine Trautmann

Last updated: 16 October 2012Legal notice